{
  "ticker": "LLY",
  "timestamp": "2025-12-01T09:17:12.234215",
  "analysis_date": "2025-01-28",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "REJECT",
  "final_position_pct": 0,
  "final_position_dollars": 0.0,
  "confidence": "LOW",
  "reasoning": "We are rejecting a position in Eli Lilly and Company (LLY) due to significant concerns regarding its current valuation and market dynamics. The stock is facing substantial downside risks, including high debt levels and signs of market saturation, which are not aligned with reasonable growth expectations. Additionally, technical indicators suggest that LLY is overbought, reinforcing our decision to prioritize risk management at this time.",
  "key_factors": [
    "Overvaluation",
    "High debt levels",
    "Market saturation"
  ],
  "conditions": [
    "Technical indicators suggest overbought conditions",
    "Low confidence from research manager"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 0.0
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "BUY",
      "neutral": "SMALL BUY",
      "conservative": "AVOID"
    },
    "position_sizes": {
      "aggressive": 7.000000000000001,
      "neutral": 20.0,
      "conservative": 0
    },
    "agreements": [],
    "conflicts": [
      "Mixed views: 2 buy, 1 avoid"
    ],
    "avg_position_size": 0.09000000000000001,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 0.0,
    "range_max_pct": 0.0,
    "final_pct": 0,
    "final_dollars": 0.0
  },
  "agent_votes": {
    "bullish": 2,
    "bearish": 1,
    "neutral": 1,
    "consensus": "LEAN_BULLISH"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2025-01-28 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: REJECT\n**Position:** No position taken\n**Confidence:** LOW\n\n## REASONING\nWe are rejecting a position in Eli Lilly and Company (LLY) due to significant concerns regarding its current valuation and market dynamics. The stock is facing substantial downside risks, including high debt levels and signs of market saturation, which are not aligned with reasonable growth expectations. Additionally, technical indicators suggest that LLY is overbought, reinforcing our decision to prioritize risk management at this time.\n\n## KEY FACTORS\n\u2022 Overvaluation\n\u2022 High debt levels\n\u2022 Market saturation\n\n## EVALUATOR SUMMARY\n- Aggressive: BUY @ 7.0%\n- Neutral: SMALL BUY @ 0.2%\n- Conservative: AVOID @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 2/4\n- Bearish Votes: 1/4\n- Neutral Votes: 1/4\n- Overall: Lean Bullish\n\n## POSITION SIZING\n- Range: 0.0% - 0.0%\n- Final: 0.00% ($0.00)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Technical indicators suggest overbought conditions\n\u2022 Low confidence from research manager\n\n======================================================================\n"
}